Studies have demonstrated overproduction of prostaglandin E2 (PGE 2 ) in CF. In vitro study show that alterations in CFTR are involved in overproduction of PGE 2 . Findings that suggest that measurement of PGE 2 production may help to assess the severity of the altered regulation of CFTR and intensity of inflammatory process in the airways of CF patients. Tetranor PGEM (PGE-M) is a metabolite present in urine that accurately reflects the biosynthesis of the PGE 2 . In this study we assessed the relationship between levels of PGE-M with CF severity. Methods: 36 patients with stable CF and 24 healthy controls were recruited. All CF patients had undergone evaluation of pancreatic function, lung function by spirometry and genotype severity. PGE-M levels were measured by a liquid chromatographic/mass spectrometric assay. Results: PGE-M concentrations were markedly and significantly elevated (p < 0.0001) in the urine of CF patients (34.5±45 ng/mgCr) compared with healthy controls (7.4±4.25 ng/mgCr). There was no correlation between PGE-M urinary levels and spirometric values. In patients with pancreatic insufficiency there was a higher PGE-M urinary level (38±7 ng/mgCr) than in patients with conserved pancreatic function (10±4.6 ng/mgCr) (p = 0.05). There was an association of the severity of genotypes with levels of PGE-M: mild: 8.6±4.1 ng/mgCr; moderate: 19.7±11 ng/mgCr; severe: 48±53.3 ng/mgCr (p < 0.0027). Conclusions: Measurement of urinary PGE-M may be a useful tool to investigate severity of CF and to assess the efficacy of any therapy aimed to improve the function of a defective CFTR.
Studies have demonstrated overproduction of prostaglandin E2 (PGE 2 ) in CF. In vitro study show that alterations in CFTR are involved in overproduction of PGE 2 . Findings that suggest that measurement of PGE 2 production may help to assess the severity of the altered regulation of CFTR and intensity of inflammatory process in the airways of CF patients. Tetranor PGEM (PGE-M) is a metabolite present in urine that accurately reflects the biosynthesis of the PGE 2 . In this study we assessed the relationship between levels of PGE-M with CF severity. Methods: 36 patients with stable CF and 24 healthy controls were recruited. All CF patients had undergone evaluation of pancreatic function, lung function by spirometry and genotype severity. PGE-M levels were measured by a liquid chromatographic/mass spectrometric assay. Results: PGE-M concentrations were markedly and significantly elevated (p < 0.0001) in the urine of CF patients (34.5±45 ng/mgCr) compared with healthy controls (7.4±4.25 ng/mgCr). There was no correlation between PGE-M urinary levels and spirometric values. In patients with pancreatic insufficiency there was a higher PGE-M urinary level (38±7 ng/mgCr) than in patients with conserved pancreatic function (10±4.6 ng/mgCr) (p = 0.05). There was an association of the severity of genotypes with levels of PGE-M: mild: 8.6±4.1 ng/mgCr; moderate: 19.7±11 ng/mgCr; severe: 48±53.3 ng/mgCr (p < 0.0027). Conclusions: Measurement of urinary PGE-M may be a useful tool to investigate severity of CF and to assess the efficacy of any therapy aimed to improve the function of a defective CFTR. Cystic Fibrosis (CF)-related diabetes (CFRD), the most common complication of CF, is preceded by a phase of low insulin secretion, glucose intolerance and accelerated decrease in weight and pulmonary function. However, no study has shown a direct link between systemic inflammation, clinical deterioration and the occurrence of CFRD in adult patients with CF. Objective: The aim of this study was to determine if interleukin (IL)-6, an important inflammatory mediator in CF as well as in diabetes, was associated to CFRD pathology. Methods: This cross-sectional study included 88 adult patients with CF (47 with normal glucose tolerance (NGT) and 41 with de novo CFRD, as determined by the oral glucose tolerance test) with a mean age of 29.7±8.4 years, an average body mass index (BMI) of 22.0±3.5 (kg/m 2 ) and %FEV 1 of 70.1±21.9, from the Montreal CF cohort (Hôtel-Dieu CHUM, Montreal, Canada). Conclusions: There was no difference in plasma levels of IL-6, as measured by enzyme-linked immunosorbent assay, between patients with NGT and with CFRD. Also, plasma IL-6 was associated to neither insulin (secretion or sensitivity) nor glucose (glucose excursion during OGTT or glycated hemoglobin) indexes of homeostasis. However, high levels of IL-6 were independently associated to pulmonary function impairment (P < 0.01), low BMI (P < 0.05) and high levels of subclinical markers of inflammation, such as C-reactive protein (P < 0.01), fibrinogen (P < 0.01), white blood cells (P < 0.01) and neutrophils (P < 0.01). Although IL-6 appears to be an important biomarker in CF-related clinical degradation, the onset of CFRD does not seem to increase its level in stable patients with CF. 
Conclusion:
Developing specific communication strategies and enhancing compliance with the official recommendations is important to improve immunization in at-risk patients and identify barriers to local vaccine implementation. The H1N1 experience should be taken into account for planning future vaccination campaigns. Centralization of the immunization at the Reference Centers for chronic diseases, as in case of CF, may represent a key strategy to improve flu vaccination coverage.
